PHE News

Precision's Goldman Addresses Mylan Firestorm in STAT News

In a new opinion piece, Precision Health Economics' Dana Goldman suggests the government can do much more in preventing the type of dramatic price hikes most recently demonstrated by Mylan for their EpiPen: "To Prevent Another EpiPen Controversy, the Government Should Step In."

READ MORE

Dana Goldman in New York Times: Concierge Care Can Help Indigent Uninsured

In Dana Goldman's latest opinion piece for the New York Times, "Hospital Care for Those Who Can Afford It Helps Care for Those Who Can't," he examines the paradox of concierge care and how it may effect those without insurance.

READ MORE

Anupam Jena in The Guardian: Australia's New Drug Guidelines Put Cost-Cutting Before Patients

Precision Health Economics' Principal Scientific Advisor Anupam B. Jena discusses Australia's new proposed drug guidlines in a new commentary for The Guardian.

READ MORE

Precision's Philipson and Shafrin in Forbes: Are You Just a Number?

In Tomas Philipson's latest Forbes.com commentary (with Precision co-author Jason Shafrin), the development of new value framework criteria are examined.

READ MORE

Precision's Chung, MacEwan, and Goldman in Health Affairs Blog: "One Size Fits All?"

Precision's Adrienne Chung, Joanna MacEwan, and Dana Goldman address formulary policy.

READ MORE
 
  • Academic Insights at

    the Speed of Business

     
  • Intellectual Integrity

    Led by professors at elite research universities, we bring intellectual integrity, academic rigor, and a creative approach to the most challenging problems in heath care.

     
  • Real World Impact

    PHE recommendations have defined and changed national and international payment policies.

     
  • Unparalleled Influence

    We frequently appear in top-tier publications and media outlets-- our work reaches top decision makers and influences outcomes.

     
  • Evidence Generation and

    Commercial Excellence

    As part of Precision for Value, our academic approach to research can be linked with a tailored, commercial approach that demonstrates the value of innovative medications.

     
  • Academic Insights at

    the Speed of Business